Literature DB >> 15067413

[Cell adhesion proteins in external auditory canal cholesteatoma].

R Naim1, F Riedel, G Bran, H Sadick, K Hörmann.   

Abstract

BACKGROUND: External auditory canal cholesteatoma (EACC) is a rare entity in otolaryngology, which is histomorphologically identical with middle ear cholesteatoma. The cause of EACCt is, however, still not clear. The aim of this study was to describe the expression of beta-catenin, MMP-2, and MMP-9 in EACC matrix compared to the normal auditory meatal skin (AMS).
METHODS: Thirteen specimens were obtained during surgical procedure. EACC and AMS specimens were immunostained with antibodies for beta-catenin, MMP-2, and MMP-9.
RESULTS: Only the basal layers of the EACC specimens were positive for beta-catenin. The suprabasal layers showed diminished or negative immunostaining for beta-catenin. In all layers, AMS was homogeneously positive for beta-catenin. In contrast, the immunostaining for the gelatinases was equally increased in all layers of EACC, whereas AMS was weekly positive.
CONCLUSION: The reduced immunoreactivity for beta-catenin may have been present because of the lessened cell-cell adhesion in the suprabasal layers of EACC. The increased expression of the metalloproteinases might point at an increased lack of integrity of EACC matrix. Recent studies revealed a balance between disintegrating and stabilising factors in normal tissue, which is disturbed in inflamed and neoplastic tissue. In EACC matrix, an imbalance of these factors, represented by reduced beta-catenin and increased gelatinase expression, is possible. Increased desquamation, the accumulation of keratin debris, and loss of tissue-stability support our findings.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15067413     DOI: 10.1007/s00106-004-1079-z

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  18 in total

Review 1.  Matrix metalloproteinases: effectors of development and normal physiology.

Authors:  T H Vu; Z Werb
Journal:  Genes Dev       Date:  2000-09-01       Impact factor: 11.361

2.  Induced expression of MMP-9 in C6 glioma cells is inhibited by PDGF via a PI 3-kinase-dependent pathway.

Authors:  Pierre-Olivier Estève; Olivier Robledo; Edouard F Potworowski; Yves St-Pierre
Journal:  Biochem Biophys Res Commun       Date:  2002-08-30       Impact factor: 3.575

3. 

Authors:  Holger Sudhoff; H Hildmann
Journal:  HNO       Date:  2003-01       Impact factor: 1.284

4.  External auditory canal wall cholesteatoma: a complication of ear surgery.

Authors:  G Venkatraman; D E Mattox
Journal:  Acta Otolaryngol       Date:  1997-03       Impact factor: 1.494

5.  [Alterations of the basal membrane in middle ear cholesteatoma].

Authors:  M Bernal Sprekelsen; J Ebmeyer; A Anonopoulos; G Borkowski; H Sudhoff
Journal:  Acta Otorrinolaringol Esp       Date:  2001-05

6.  Angiogenesis and angiogenic growth factors in middle ear cholesteatoma.

Authors:  H Sudhoff; S Dazert; A M Gonzales; G Borkowski; S Y Park; A Baird; H Hildmann; A F Ryan
Journal:  Am J Otol       Date:  2000-11

7.  Proteinase suppression by E-cadherin-mediated cell-cell attachment in premalignant oral keratinocytes.

Authors:  Hidayatullah G Munshi; Supurna Ghosh; Subhendu Mukhopadhyay; Yi I Wu; Ratna Sen; Kathleen J Green; M Sharon Stack
Journal:  J Biol Chem       Date:  2002-07-23       Impact factor: 5.157

8.  Keratosis obturans and external auditory canal cholesteatoma.

Authors:  M C Piepergerdes; B M Kramer; E E Behnke
Journal:  Laryngoscope       Date:  1980-03       Impact factor: 3.325

9.  The pathologic features of keratosis obturans and cholesteatoma of the external auditory canal.

Authors:  J Naiberg; G Berger; M Hawke
Journal:  Arch Otolaryngol       Date:  1984-10

10.  Expression of epidermal growth factor, tumor necrosis factor-alpha, and interleukin-1alpha in chronic otitis media with or without cholesteatoma.

Authors:  Sertac Yetiser; Bulent Satar; Nizamettin Aydin
Journal:  Otol Neurotol       Date:  2002-09       Impact factor: 2.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.